break out the champagne, page-2

Great to see ACL finally improving on decent volume post the SPP announcement.

At current prices I think the market has priced in such dismal expectations of Fonda revenue that any half decent update on sales should give rise to a decent pop in the SP, and hard to see what kind of material value is being placed on our oncology assets, decent Ph111 updates should again force Mr Market to wipe out the deep discount built into the SP.

Hopefully we dont see a wave of selling after the retail SPP if hopefully timed with some good news. But could be very risky for those sitting on the sidelines waiting for pullbacks given news flow may quickly unwind the deep discount that may not be around for too long. Perhaps the smart money is already coming in.

Other speccys have bounced back hard from the recent risk sell off and the opportunity cost has been tough to swallow, but with capital raising risks soon to be out of the way hopefully we see a continued bounce from here.